In last trading session, Sutro Biopharma Inc (NASDAQ:STRO) saw 0.46 million shares changing hands with its beta currently measuring 1.20. Company’s recent per share price level of $1.77 trading at -$0.06 or -3.28% at ring of the bell on the day assigns it a market valuation of $145.95M. That closing price of STRO’s stock is at a discount of -246.33% from its 52-week high price of $6.13 and is indicating a premium of 14.69% from its 52-week low price of $1.51.

For Sutro Biopharma Inc (STRO), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.18. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.95 in the current quarter.

Sutro Biopharma Inc (NASDAQ:STRO) trade information

Upright in the red during last session for losing -3.28%, in the last five days STRO remained trading in the green while hitting it’s week-highest on Tuesday, 02/18/25 when the stock touched $1.77 price level, adding 9.0% to its value on the day. Sutro Biopharma Inc’s shares saw a change of -3.80% in year-to-date performance and have moved 1.72% in past 5-day. Sutro Biopharma Inc (NASDAQ:STRO) showed a performance of -10.15% in past 30-days.

Wall Street analysts have assigned a consensus price target of 12 to the stock, which implies a rise of 85.25% to its current value. Analysts have been projecting 12 as a low price target for the stock while placing it at a high target of 12. It follows that stock’s current price would drop -577.97% in reaching the projected high whereas dropping to the targeted low would mean a loss of -577.97% for stock’s current value.

Sutro Biopharma Inc (STRO) estimates and forecasts

This year revenue growth is estimated to fall -61.49% from the last financial year’s standing.

11 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 12.18M for the same. And 6 analysts are in estimates of company making revenue of 9M in the next quarter. Company posted 113.72M and 13.01M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 21.96% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -62.82% while estimates for its earnings growth in next 5 years are of -17.31%.

Sutro Biopharma Inc (NASDAQ:STRO)’s Major holders

SUVRETTA CAPITAL MANAGEMENT, LLC is the top institutional holder at STRO for having 7.71 million shares of worth $22.59 million. And as of 2024-06-30, it was holding 9.4906 of the company’s outstanding shares.

The second largest institutional holder is BLACKROCK INC., which was holding about 6.91 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.5082 of outstanding shares, having a total worth of $20.25 million.

On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 2.42 shares of worth $4.28 million or 2.93% of the total outstanding shares. The later fund manager was in possession of 2.27 shares on Nov 30, 2024 , making its stake of worth around $4.02 million in the company or a holder of 2.75% of company’s stock.